Huntington National Bank’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $38.7K | Sell |
748
-6
| -0.8% | -$306 | ﹤0.01% | 1432 |
|
|
2025
Q4 | $37.5K | Buy |
754
+114
| +18% | +$5.54K | ﹤0.01% | 1360 |
|
|
2025
Q3 | $30.6K | Sell |
640
-252
| -28% | -$10.1K | ﹤0.01% | 1452 |
|
|
2025
Q2 | $28.1K | Buy |
892
+68
| +8% | +$2.18K | ﹤0.01% | 1456 |
|
|
2025
Q1 | $27K | Buy |
824
+46
| +6% | +$1.63K | ﹤0.01% | 1425 |
|
|
2024
Q4 | $28.1K | Buy |
778
+32
| +4% | +$1.13K | ﹤0.01% | 1438 |
|
|
2024
Q3 | $23.3K | Sell |
746
-2
| -0.3% | -$62 | ﹤0.01% | 1461 |
|
|
2024
Q2 | $20K | Sell |
748
-12
| -2% | -$348 | ﹤0.01% | 1456 |
|
|
2024
Q1 | $25.9K | Buy |
760
+117
| +18% | +$3.48K | ﹤0.01% | 1381 |
|
|
2023
Q4 | $18.6K | Buy |
643
+2
| +0.3% | +$53 | ﹤0.01% | 1436 |
|
|
2023
Q3 | $17.7K | Sell |
641
-36
| -5% | -$1.1K | ﹤0.01% | 1396 |
|
|
2023
Q2 | $20.4K | Sell |
677
-12
| -2% | -$420 | ﹤0.01% | 1355 |
|
|
2023
Q1 | $25K | Sell |
689
-13
| -2% | -$500 | ﹤0.01% | 1240 |
|
|
2022
Q4 | $25K | Sell |
702
-112
| -14% | -$3.89K | ﹤0.01% | 1211 |
|
|
2022
Q3 | $28K | Hold |
814
| – | – | ﹤0.01% | 1172 |
|
|
2022
Q2 | $24K | Buy |
814
+557
| +217% | +$16K | ﹤0.01% | 1264 |
|
|
2022
Q1 | $8K | Hold |
257
| – | – | ﹤0.01% | 1670 |
|
|
2021
Q4 | $7K | Buy |
257
+85
| +49% | +$2.58K | ﹤0.01% | 1677 |
|
|
2021
Q3 | $5K | Hold |
172
| – | – | ﹤0.01% | 1575 |
|
|
2021
Q2 | $5K | Hold |
172
| – | – | ﹤0.01% | 1569 |
|
|
2021
Q1 | $5K | Hold |
172
| – | – | ﹤0.01% | 1460 |
|
|
2020
Q4 | $4K | Hold |
172
| – | – | ﹤0.01% | 1441 |
|
|
2020
Q3 | $4K | Hold |
172
| – | – | ﹤0.01% | 1367 |
|
|
2020
Q2 | $4K | Sell |
172
-461
| -73% | -$10.2K | ﹤0.01% | 1348 |
|
|
2020
Q1 | $11K | Buy |
633
+245
| +63% | +$5.15K | ﹤0.01% | 1178 |
|
|
2019
Q4 | $9K | Sell |
388
-83
| -18% | -$2.02K | ﹤0.01% | 1430 |
|
|
2019
Q3 | $13K | Hold |
471
| – | – | ﹤0.01% | 1227 |
|
|
2019
Q2 | $16K | Sell |
471
-4,014
| -89% | -$138K | ﹤0.01% | 1217 |
|
|
2019
Q1 | $157K | Buy |
4,485
+4,028
| +881% | +$150K | ﹤0.01% | 564 |
|
|
2018
Q4 | $15K | Buy |
457
+161
| +54% | +$6.92K | ﹤0.01% | 1209 |
|
|
2018
Q3 | $15K | Sell |
296
-793
| -73% | -$39.2K | ﹤0.01% | 1305 |
|
|
2018
Q2 | $65K | Sell |
1,089
-13
| -1% | -$673 | ﹤0.01% | 859 |
|
|
2018
Q1 | $50K | Buy |
1,102
+908
| +468% | +$37.9K | ﹤0.01% | 950 |
|
|
2017
Q4 | $8K | Sell |
194
-23
| -11% | -$909 | ﹤0.01% | 1394 |
|
|
2017
Q3 | $9K | Hold |
217
| – | – | ﹤0.01% | 1376 |
|
|
2017
Q2 | $9K | Buy |
+217
| New | +$7.72K | ﹤0.01% | 1306 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Huntington National Bank's SUPN Position: Q1 2026 in Review
Huntington National Bank reduced its Supernus Pharmaceuticals (SUPN) stake by 0.8% in Q1 2026, selling an estimated $306 and leaving 748 shares worth $38.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.
Huntington National Bank first reported a position in SUPN in Q2 2017 and has held it in 36 quarters since. The position peaked at $157K in Q1 2019. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Huntington National Bank held 748 shares of Supernus Pharmaceuticals worth $38.7K as of Q1 2026.
- Huntington National Bank sold 6 Supernus Pharmaceuticals shares in Q1 2026, an estimated $306.
- Supernus Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1432 holding.
- Huntington National Bank first reported a position in Supernus Pharmaceuticals in Q2 2017 and has held it in 36 quarters since.
- Huntington National Bank's Supernus Pharmaceuticals position peaked at $157K in Q1 2019.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.